Clinical Trial Update: Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial results for levomilnacipran ER (F2695 SR) in major depressive disorder assessing safety and efficacy; the study has completed and results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• FETZIMA (levomilnacipran hydrochloride)

Snippet

Sponsor: Forest Laboratories | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2013-10-25